BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Figure 1

Targeting BRCA1 as a therapeutic strategy in the treatment of EOC. BRCA1 is central to the DNA damage response which is initiated following insults such as platinum-based chemotherapeutic agents. Various small molecule inhibitors may target BRCA1 directly or indirectly, ultimately leading to failure to repair damaged DNA and apoptosis.